Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Therapeutic Advances in Neurological Disorders|August 4, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS StudyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Cell Reports Methods|August 3, 2023
A structured evaluation of cryopreservation in generating single-cell transcriptomes from cerebrospinal fluidHanane Touil, Tina Roostaei, Daniela Calini, et al.
Neurology and Therapy|July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS StudyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology|February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
The Journal of Experimental Medicine|September 12, 2007
Neurofascin as a novel target for autoantibody-mediated axonal injuryEmily K Mathey, Tobias Derfuss, Maria K Storch, et al.
Frontiers in Immunology|March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 4, 2026
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension studyNicola De Stefano, Patrick Vermersch, Heinz Wiendl, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2009
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animalsTobias Derfuss, Khyati Parikh, Sviataslau Velhin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 21, 2022
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS SubstudyHeinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, et al.
Neurology|May 31, 2015
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSLudwig Kappos, Ernst-Wilhelm Radue, Giancarlo Comi, et al.
Pageof 17